We identify and fund transformative life science opportunities in emerging and under-ventured research hubs within the US and UK. We often partner with leading universities and research institutions to provide much needed capital for their most innovative ideas.

Our aim is to build extraordinary companies that transform novel science into the next generation of highly successful drugs and medical devices.

As founding investors, we provide seed or Series A funds to spin out innovations from highly regarded medical research universities and institutions in the US and UK. The companies we build have a strong track record of attracting follow-on investment from top tier funds.

We invest in most areas of life science including biotechnology and pharmaceuticals, medical devices and health tech.

We are building a diverse portfolio of companies that are translating exciting science for the benefit of patients while generating exceptional returns to our investors.

Key factors that we consider in our evaluation include:

• Disruptive platform technologies that address large and unmet medical needs.
• Novel innovations that offer a sustainable competitive advantage.
• Future pipeline of high value products deliverable to the patient or customer.
• Robust Intellectual Property portfolios (patents, trade secrets and “know how”).
• Prospective commercial partners and early evidence of market validation.
• Early traction and support from key opinion leaders and health practitioners.
• Clear regulatory (and where applicable, insurance reimbursement) strategies.
• Efficient use of capital.
• Highly driven and tenacious founders and entrepreneurs.
• Potential for outstanding financial return and significant patient impact.